Kinase inhibitor

Patent metadata

Field	Value
Publication number	US-9499486-B2
Application number	US-201514872807-A
Country	US
Kind code	B2
Filing date	Oct 1, 2015
Priority date	Oct 1, 2014
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

There is provided a compound of formula I,

which compound has anti-inflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and has use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

First claim

The invention claimed is:

1. A compound of formula I,

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 that is 4-((4-((4-(3-(5-(tert-butyl)-2-methoxy-3-(methylsulfonamido)phenyl)ureido)naphthalen-1-yl)oxy)pyridin-2-yl)amino)-2-methoxybenzoic acid.

3. A pharmaceutical formulation comprising a compound as defined in claim 1 , or pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

4. A combination product comprising
(A) a compound as defined in claim 1 , or pharmaceutically acceptable salt thereof, and
(B) another therapeutic agent,

wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

5. A method of treating an inflammatory disease, said method comprising administering to a subject an effective amount of a compound as defined in claim 1 , or pharmaceutically acceptable salt thereof, or a pharmaceutical formulation as defined in claim 3 , or a combination product as defined claim 4 .

6. A method according to claim 5 , wherein the inflammatory disease is selected from the group consisting of cystic fibrosis, pulmonary hypertension, lung sarcoidosis, idiopathic pulmonary fibrosis, COPD, chronic bronchitis, emphysema, asthma, paediatric asthma, atopic dermatitis, allergic dermatitis, contact dermatitis or psoriasis, allergic rhinitis, rhinitis, sinusitis, conjunctivitis, allergic conjunctivitis, keratoconjunctivitis sicca, dry eye, xerophthalmia, glaucoma, diabetic retinopathy, macular oedema, diabetic macular oedema, central retinal vein occlusion (CRVO), dry and/or wet age related macular degeneration (AMD), post-operative cataract inflammation, uveitis, posterior uveitis, anterior uveitis, pan uveitis, corneal graft and limbal cell transplant rejection, gluten sensitive enteropathy (coeliac disease), eosinophilic esophagitis, intestinal graft versus host disease, Crohn's disease and ulcerative colitis.

7. A method according to claim 5 , wherein the inflammatory disease is uveitis, keratoconjunctivitis sicca, dry eye, xerophthalmia, Crohn's disease or ulcerative colitis.

8. A method according to claim 5 , wherein the inflammatory disease is keratoconjunctivitis sicca, dry eye or xerophthalmia.

9. A process for the preparation of a compound of formula I:

which process comprises:
(a) reacting a compound of formula II,

with a compound of formula III,

wherein one of Z 1 and Z 2 is a structural fragment of formula IV

and the other of Z 1 and Z 2 is a structural fragment of formula V

(b) reacting a compound of formula IIa,

wherein Z 1 is as defined above, with a suitable azide-forming agent,
which reaction is followed, without isolation, by thermal rearrangement of the intermediate acyl azide (of formula Z 1 —C(O)—N 3 ) to provide, in situ, a compound of formula II, which compound is then reacted with a compound of formula III as defined above;

(c) reacting a compound of formula IIb,

wherein LG 1 represents a leaving group and Z 1 is as defined above, with a compound of formula III, as defined above;

(d) reacting a compound of formula VI,

wherein LG 2 represents a leaving group, with a compound of formula VII,

 or
(e) deprotecting a protected derivative of the compound of formula I, wherein the protected derivative bears a protecting group on an O— or N-atom of the compound of formula I.

10. A process according to claim 9 , wherein the protected derivative of the compound of formula I is a compound of formula VIIa,

wherein Q X represents —C(O)O—C 1-4 alkyl.

Assignees

• Respivert Ltd
• Topivert Pharma Ltd

Inventors

• Fyfe Matthew Colin Thor

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title